Clinical trials: Rectum Neoplasms
Colorectal Neoplasms, Stomach Neoplasms
Proteomic Analysis of HLA Complex in Solid Cancers: Breast, Ovary, Colon, Rectum, Stomach, and Pancreas
The purpose of this study is to evaluate the presence of proteins in solid tumors which may lead to an immune response
- Conditions
- Colorectal Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Breast Neoplasms
- Trial name
- NCT00419627
- Where
- Israel
- Volunteers
- 160 people
- Sponsor
- Hillel Yaffe Medical Center
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Colonic Cancer, Rectal Cancer
National Registry of Liver First Approach
Liver metastases are present in 15-25% of patients with colorectal cancer at the time of diagnosis of the primary tumor, which is defined as synchronous liver metastases.
- Conditions
- Colonic Cancer, Rectal Cancer, Liver Metastases
- Trial name
- RENACI (NCT04683783)
- Where
- Spain
- Volunteers
- 168 people
- Sponsor
- Hospital Miguel Servet
Neoplasms, Colorectal Neoplasms
Study of PRoliferation and Apoptosis in Rectal Cancer, Predictive & Prognostic biOmarkers: Histopathology and Imaging
This study tests biopsy and tissue from patients who have been treated for primary rectal cancer at the Royal Marsden Hospital between 2011 and 2013, who have an mrTRG score at post-chemoradiotherapy MRI.
- Conditions
- Neoplasms, Colorectal Neoplasms, Rectal Diseases, Gastrointestinal Neoplasms
- Trial name
- SOPRANO (NCT02486094)
- Where
- United Kingdom
- Volunteers
- 148 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Recurrent Rectal Cancer
Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer
The study is a prospective, single-center, single-arm, phase II clinical trial. Patients with pelvic recurrent rectal cancer aged from 18 to 75 years, Eastern Cooperative Oncology Group performance status of 0-1, will receive…
- Trial name
- TRACER (NCT06751394)
- Testing
- PD-1 antibody (Toripalimab), Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Rectal Cancer
Anterior Resection Syndrome Following Sphincter-preserving Surgery
Bowel cancer is the third most common cancer in the UK in both males and females. The rectum is the most commonly affected part of the bowel.
- Trial name
- NCT02190656
- Where
- United Kingdom
- Volunteers
- 1,197 people
- Sponsor
- Queen Mary University of London
Rectal Neoplasm Malignant Carcinoma, Chemoradiotherapy
Study on Predictive Biomarkers of Neoadjuvant Chemoradiotherapy for Rectal Cancer
Backgrounds: A multicenter randomized phase III trial (NCT02605265) proved that adding irinotecan guided by UGT1A1 to capecitabine-based neoadjuvant chemoradiotherapy significantly increases complete tumor response.
- Conditions
- Rectal Neoplasm Malignant Carcinoma, Chemoradiotherapy, Neoadjuvant Therapy, Predictive Biomarkers
- Trial name
- NCT04227886
- Testing
- Radiation, Capecitabine-Irinotecan Combination
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fudan University
Rectal Neoplasms Malignant
Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly
The aim of this multicenter phase II study is to evaluate the response rate, local control, disease-free survival and treatment-related toxicity of preoperative chemoradiation for intermediate or locally advanced rectal cancer in…
- Trial name
- NCT02992886
- Testing
- Preoperative radiation, Raltitrexed, Pelvic surgery
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Chinese Academy of Medical Sciences
Colorectal Cancer, Metastatic Cancer
Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with surgery may kill more tumor cells.
- Trial name
- NCT00006479
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- 111 sites in Australia, Austria and 11 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer
This phase II trial studies how long it takes colorectal cancer resistant to standard treatment to grow while receiving treatment with ziv-aflibercept, and how well adding fluorouracil and leucovorin calcium to ziv-aflibercept…
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT02235324
- Testing
- ziv-aflibercept, leucovorin calcium, fluorouracil
- Where
- United States
- Sponsor
- University of Southern California
Breast Neoplasm, Prostate Neoplasm
Evaluating the Impact of Financial Navigation on Financial Catastrophe and Distress for Cancer Care
The goal of this study is to investigate the effectiveness of a structured financial navigation program in reducing financial catastrophe and financial distress for cancer patients in Nigeria.
- Conditions
- Breast Neoplasm, Prostate Neoplasm, Colon Neoplasm, Rectal Neoplasm
- Trial name
- COST-FIN (NCT06630962)
- Testing
- Financial Navigation Program
- Where
- 2 sites in Nigeria
- Volunteers
- 200 people
- Sponsor
- Northwestern University
Rectal Cancer
Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy
This is an open-label, multi-center, single-arm clinical study. All patients received 4-6 cycles total neoadjuvant therapy plus concurrent tislelizumab immunotherapy, then underwent clinical response assessment.
- Trial name
- TNTIT (NCT07561060)
- Testing
- Tislelizumab, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Rectal Cancer
Fluorescent Lymphography-Guided Lymphadenectomy In Laparoscopic Proctectomy
The purpose of this study is to compare the number of lymph nodes retrieved with or without the use of intraoperative fluorescence lymphography in laparoscopic radical resection of rectal cancer.
- Trial name
- NCT03854890
- Testing
- Indocyanine Green
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Rectal Neoplasms
Rectrospect - a Retrospective Study of Treatment Response
Biopisies from patients diagnosed with rectal cancer between 2007-2019 will be cut into 4-6 micrometer thin sections for morphology and immunostaining.
- Trial name
- Rectrospect (NCT04787523)
- Testing
- Radiotherapy
- Where
- Sweden
- Volunteers
- 170 people
- Sponsor
- Sahlgrenska University Hospital
Rectal Cancer
The Stockholm III Trial on Different Preoperative Radiotherapy Regimens in Rectal Cancer
Preoperative radiotherapy (RT) is recommended to many patients with localised rectal cancer, not previously treated with pelvic RT.
- Trial name
- Stockholm III (NCT00904813)
- Testing
- Short-course RT, Long-course RT
- Where
- 18 sites in Sweden
- Volunteers
- 840 people
- Sponsor
- Karolinska Institutet
Locally Advanced Cancer in the Anal Region
Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0
To establish maximum tolerated dose of the two cytotoxic drugs 5-fluoruracil and mitomycin C when given together with the antibody cetuximab in patients with locally advanced cancer in the anal region To evaluate acute toxicity…
- Trial name
- NOAC8 (NCT01621217)
- Testing
- Cetuximab, Mitomycin C, 5-Fluoruracil
- Where
- 3 sites in Norway, Sweden
- Volunteers
- 21 people
- Sponsor
- Lund University Hospital
Advanced Solid Tumor, Anal Cancer
Phase 1 Study of Oral TP-1454
This study will evaluate the safety and tolerability of oral TP-1454 in patients with advanced metastatic or progressive solid tumors and anal cancer.
- Trial name
- NCT04328740
- Testing
- TP-1454 monotherapy
- Where
- 11 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sumitomo Pharma America, Inc.
Anal Cancer
Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00955240
- Testing
- cetuximab, cisplatin, fluorouracil
- Where
- 20 sites in France
- Volunteers
- 16 people
- Sponsor
- UNICANCER
Rectal Cancer
Reasons for Non-reversal of Temporary Stomas After Surgeries of Mid-low Rectal Cancer （NORESTO Study）
The goal of this observational study is to learn about in mid-low rectal patients who received temporary ostomies after surgery of the primary tumors.
- Trial name
- NCT06194708
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Peking Union Medical College Hospital
Genital Wart, Penile Cancer
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Human Papillomavirus (HPV) Recombinant Vaccine (Hansenula Polymorpha) in Chinese male…
- Conditions
- Genital Wart, Penile Cancer, Anal Cancer, PIN-1
- Trial name
- NCT06465914
- Testing
- 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
- Where
- 5 sites in China
- Volunteers
- 9,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.